- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06203990
Barre Exercise in Parkinson's
June 10, 2025 updated by: Gammon M Earhart, Washington University School of Medicine
Barre Exercise for People With Parkinson Disease
This study asks if a barre exercise program is a feasible and acceptable form of exercise for individuals with Parkinson disease.
The study will also evaluate barre's potential effects on motor outcomes, including balance, strength, and functional mobility.
Study Overview
Detailed Description
The primary objectives of this study are to: 1) evaluate the feasibility and acceptability of a barre exercise intervention and 2) gather preliminary data regarding the effect of a barre exercise intervention on balance, strength, functional mobility and quality of life in individuals with mild to moderate Parkinson disease (PD).
Individuals with PD (N=15) will be recruited to participate in a pilot barre exercise class led by a certified barre instructor.
The intervention will include 24, 45-50 minute group classes (twice weekly for 12 weeks, excluding holidays).
Pre- and post-intervention data collection will include assessments of balance, lower extremity strength, and functional mobility.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63108
- Washington University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- diagnosed by a neurologist with idiopathic Parkinson disease
- at least 18 years of age
- a score on the Hoehn & Yahr (H&Y) scale between I-III to indicate mild to moderate disease severity
- able to provide informed consent
- able to walk for 10 continuous minutes without assistance from another person
- stable medication regimen for at least one month prior to enrollment
Exclusion Criteria:
- any neurological condition other than PD
- history of orthopedic or other medical conditions that limit the ability to safely participate in the intervention or
- language, visual, or hearing barriers to participation
- evidence of dementia (Montreal Cognitive Assessment < 24) to ensure understanding of the intervention class instructions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Barre class
Barre is an exercise modality that combines elements of classical ballet with strength training.
Barre involves high repetitions of low impact, isometric movements, requires little to no equipment, and is highly modifiable for different fitness levels.
Barre is traditionally performed in a class setting, which promotes increased social interaction and builds community.
Furthermore, interventions with dance elements exhibit high adherence rates (often > 80%).The exercises in a barre class are also performed holding on to a fixed barre or on the floor, which may address people with PD's fear of falling.
|
Group barre exercise class
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attendance
Time Frame: 12 weeks
|
Number of participants who attended at least 75% of the classes
|
12 weeks
|
|
Retention (Study Completion)
Time Frame: 12 weeks
|
Percent of participants who remained enrolled for the duration of the study
|
12 weeks
|
|
Acceptability
Time Frame: 12 weeks
|
Mean group rating on the Client Satisfaction Questionnaire, a standardized measure using Likert-scale questions to assess self-reported satisfaction of a program.
Range is 1-4, higher scores indicate higher satisfaction
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Balance
Time Frame: 12 weeks
|
Mean change in total score on the Mini Balance Evaluation Systems Test (Mini-BESTest) from pre- to post-intervention.
The Mini-BESTest is a brief, clinically relevant assessment of balance, scored on a scale from 0 to 28, with higher scores indicating better balance.
A negative change score reflects a decline in balance performance from pre- to post-intervention.
|
12 weeks
|
|
Functional Strength
Time Frame: 12 weeks
|
Mean change in time taken to complete five sit to stand movements pre- to post- intervention, measured in seconds.
Longer time indicates worse performance.
|
12 weeks
|
|
Gait
Time Frame: 12 weeks
|
Mean change in gait speed pre- to post-intervention, measured in meters/second.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 29, 2024
Primary Completion (Actual)
May 24, 2024
Study Completion (Actual)
May 24, 2024
Study Registration Dates
First Submitted
January 2, 2024
First Submitted That Met QC Criteria
January 2, 2024
First Posted (Actual)
January 12, 2024
Study Record Updates
Last Update Posted (Actual)
June 26, 2025
Last Update Submitted That Met QC Criteria
June 10, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202312097
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Bezmialem Vakif UniversityIstanbul University - CerrahpasaNot yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
Clinical Trials on Barre exercise
-
Riphah International UniversityCompletedDysmenorrhea PrimaryPakistan
-
Idaho State UniversityCompletedMusculoskeletal Disorders | Perceived Stress | Stress Management | Reported Stress | Perceived Pain | Reported PainUnited States
-
Superior UniversityActive, not recruitingPsychology, SocialPakistan
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
University of Texas, El PasoRecruitingKnee Osteoarthritis | Knee Pain Chronic | Central Pain SyndromeUnited States
-
Aksaray University Training and Research HospitalCompletedExercise Training | Lactate Blood Increase | Cognitive Functions | BDNFTurkey (Türkiye)
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada
-
University of Alabama at BirminghamCompletedCystic FibrosisUnited States
-
University College CorkRecruitingDepressive Disorder, MajorIreland
-
Sahmyook UniversityRecruitingChronic Nonspecific Neck PainKorea, Republic of